Document is current
Any future updates will be listed below
-
Authors
Iori, Anna Paola
De Vivo, Antonio https://orcid.org/0000-0001-6022-0003
Di Bona, Eros
Caocci, Giovanni https://orcid.org/0000-0002-6585-5187
Fioritoni, Francesca
Ciceri, Fabio
Beggiato, Eloise https://orcid.org/0000-0002-2971-7596
Rapezzi, Davide https://orcid.org/0009-0004-0907-2905
Amendola, Angela
Figuera, Amalia
Selleri, Carmine https://orcid.org/0000-0002-5861-8984
Longu, Francesco
Fattizzo, Bruno https://orcid.org/0000-0003-0857-8379
Tucci, Alessandra https://orcid.org/0000-0003-3052-7463
Cignetti, Alessandro
Amico, Valeria
Sica, Simona https://orcid.org/0000-0003-2426-3465
Metafuni, Elisabetta
Raso, Simona https://orcid.org/0000-0002-0967-2191
Urbano, Tiziana Anna
Marano, Luana https://orcid.org/0009-0000-1841-9887
Di Renzo, Nicola
Spedini, Pierangelo
Rambaldi, Alessandro
Lanza, Francesco https://orcid.org/0000-0002-5189-7167
Clissa, Cristina
Danesin, Cristina
Greve, Maria Bruna https://orcid.org/0000-0002-0292-4050
Cabibbo, Sergio
Ori, Alessandra https://orcid.org/0009-0004-2030-3866
Cassanelli, Francesca https://orcid.org/0000-0003-2253-7653
Sottana, Federica
Campolo, Benedetta
Gasparri, Giulia
Carini, Fabio
Barcellini, Wilma https://orcid.org/0000-0003-1428-9944
-
Funding
Funding for this research was provided by:
Alexion Pharma Italy
- License Information
-
More Information
Article History
Received: 1 August 2025
Accepted: 19 November 2025
First Online: 22 January 2026
Declarations
:
: The study was approved by the ethics committees of all participating institutions before the start of data collection and conducted under the guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements.
: All participants received a comprehensive explanation of the study procedures and goals, consistent with the Declaration of Helsinki (1964 and its later amendments), and voluntarily participated in this study after signing a written informed consent form.
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Simona Raso: Advisory board honoraria and speaker’s bureau from Alexion and Sobi;Maria Bruna Greve: Advisory board participation for Sobi;Alessandra Ori and Francesca Cassanelli are employees of IQVIA Solutions Italy S.r.l.;Benedetta Campolo is an employee of Alexion Pharma;Fabio Carini, Giulia Gasparri and Federica Sottana are employees of Alexion Pharma Italy.All other authors have no competing interests to disclose.
